These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16472049)

  • 1. An overview of inflammatory markers in type 2 diabetes from the perspective of the clinical chemist.
    Kimberly MM; Cooper GR; Myers GL
    Diabetes Technol Ther; 2006 Feb; 8(1):37-44. PubMed ID: 16472049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus.
    Pfützner A; Forst T
    Diabetes Technol Ther; 2006 Feb; 8(1):28-36. PubMed ID: 16472048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial.
    Schaumberg DA; Glynn RJ; Jenkins AJ; Lyons TJ; Rifai N; Manson JE; Ridker PM; Nathan DM
    Circulation; 2005 May; 111(19):2446-53. PubMed ID: 15867184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM; Silvertown JD
    J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ
    Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein: a nontraditional serum marker of cardiovascular risk.
    de Ferranti SD; Rifai N
    Cardiovasc Pathol; 2007; 16(1):14-21. PubMed ID: 17218210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
    Sellmayer A; Limmert T; Hoffmann U
    Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study.
    Best LG; Zhang Y; Lee ET; Yeh JL; Cowan L; Palmieri V; Roman M; Devereux RB; Fabsitz RR; Tracy RP; Robbins D; Davidson M; Ahmed A; Howard BV
    Circulation; 2005 Aug; 112(9):1289-95. PubMed ID: 16116058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Widespread statin use recommended for patients with type 2 diabetes.
    Voelker R
    JAMA; 2004 May; 291(20):2419-20. PubMed ID: 15161877
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum high sensitivity C-reactive protein is associated with carotid intima-media thickness in type 2 diabetes.
    Kang ES; Kim HJ; Kim YM; Lee S; Cha BS; Lim SK; Kim HJ; Lee HC
    Diabetes Res Clin Pract; 2004 Dec; 66 Suppl 1():S115-20. PubMed ID: 15563960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of C-reactive protein with body fat, diabetes and coronary artery disease in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-6).
    Mohan V; Deepa R; Velmurugan K; Premalatha G
    Diabet Med; 2005 Jul; 22(7):863-70. PubMed ID: 15975100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-sensitivity C-reactive protein levels and type 2 diabetes in urban North Indians.
    Mahajan A; Tabassum R; Chavali S; Dwivedi OP; Bharadwaj M; Tandon N; Bharadwaj D
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2123-7. PubMed ID: 19336513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches.
    Tousoulis D; Papageorgiou N; Androulakis E; Siasos G; Latsios G; Tentolouris K; Stefanadis C
    J Am Coll Cardiol; 2013 Aug; 62(8):667-76. PubMed ID: 23948511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of high sensitivity C-reactive protein in cardiology.
    Adukauskienė D; Čiginskienė A; Adukauskaitė A; Pentiokinienė D; Šlapikas R; Čeponienė I
    Medicina (Kaunas); 2016; 52(1):1-10. PubMed ID: 26987494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.
    Guijarro C
    Circulation; 2001 Nov; 104(22):E127. PubMed ID: 11723039
    [No Abstract]   [Full Text] [Related]  

  • 17. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.
    Ridker PM
    J Am Coll Cardiol; 2007 May; 49(21):2129-38. PubMed ID: 17531663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Sensitivity C-Reactive Protein and Statin Initiation.
    Trpkovic A; Stanimirovic J; Rizzo M; Resanovic I; Soskic S; Jevremovic D; Isenovic ER
    Angiology; 2015 Jul; 66(6):503-7. PubMed ID: 25053677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein and cardiovascular diseases--is it ready for primetime?
    Lavie CJ; Milani RV; Verma A; O'Keefe JH
    Am J Med Sci; 2009 Dec; 338(6):486-92. PubMed ID: 20010156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study.
    Lowe G; Woodward M; Hillis G; Rumley A; Li Q; Harrap S; Marre M; Hamet P; Patel A; Poulter N; Chalmers J
    Diabetes; 2014 Mar; 63(3):1115-23. PubMed ID: 24222348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.